Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Goethe University Frankfurt · Universitat Autònoma de Barcelona · +2 more institutions
Abstract
Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects.
In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standard-of-care chemotherapy. The primary end point was overall survival.
Citation impact
- FWCI
- 173.07
- Percentile
- 100%
- References
- 41
Authors
26- HKHagop KantarjianCorresponding
Goethe University Frankfurt, Universitat Autònoma de Barcelona, City Of Hope National Medical Center, University College London
- ASAnthony S. Stein
Goethe University Frankfurt, Universitat Autònoma de Barcelona, City Of Hope National Medical Center, University College London
- NGNicola Gökbuget
Goethe University Frankfurt, Universitat Autònoma de Barcelona, City Of Hope National Medical Center, University College London
- AKAdele K. Fielding
Goethe University Frankfurt, Universitat Autònoma de Barcelona, City Of Hope National Medical Center, University College London
- ACAndre C. Schuh
Goethe University Frankfurt, Universitat Autònoma de Barcelona, City Of Hope National Medical Center, University College London
Topics & keywords
- Blinatumomab
- Medicine
- Chemotherapy
- Hazard ratio
- Internal medicine
- Acute lymphocytic leukemia
- Oncology
- Leukemia
- Good health and well-being